Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 1,652 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,652 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $202.84, for a total transaction of $335,091.68. Following the sale, the insider directly owned 140,643 shares of the company’s stock, valued at $28,528,026.12. This represents a 1.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The shares were sold at an average price of $203.69, for a total transaction of $693,564.45.
• On Monday, April 27th, Solomon Moshkevich sold 2,182 shares of Natera stock. The shares were sold at an average price of $204.10, for a total value of $445,346.20.
• On Wednesday, April 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $202.30, for a total value of $606,900.00.
• On Tuesday, March 10th, Solomon Moshkevich sold 915 shares of Natera stock. The shares were sold at an average price of $204.13, for a total value of $186,778.95.
• On Monday, March 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $199.85, for a total value of $599,550.00.

Natera Price Performance

Shares of NTRA opened at $213.94 on Friday. The company has a market capitalization of $30.64 billion, a price-to-earnings ratio of -131.25 and a beta of 1.57. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36. The business’s 50-day moving average is $201.85 and its 200-day moving average is $215.63.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. The company had revenue of $665.50 million for the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.During the same quarter in the prior year, the company earned ($0.41) EPS. Equities research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Natera

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its position in shares of Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after acquiring an additional 1,225,420 shares during the period. Wellington Management Group LLP boosted its position in shares of Natera by 94.7% in the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after acquiring an additional 2,420,263 shares during the period. State Street Corp boosted its position in shares of Natera by 2.2% in the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after acquiring an additional 72,087 shares during the period. Franklin Resources Inc. boosted its position in shares of Natera by 37.5% in the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after acquiring an additional 727,366 shares during the period. Finally, Coatue Management LLC boosted its position in shares of Natera by 1,446.1% in the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after acquiring an additional 2,463,008 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on NTRA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. Morgan Stanley dropped their price objective on Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. Evercore restated an “outperform” rating and issued a $270.00 price objective on shares of Natera in a report on Friday, May 8th. Piper Sandler restated an “overweight” rating and issued a $249.00 price objective on shares of Natera in a report on Tuesday, May 12th. Finally, JPMorgan Chase & Co. increased their price objective on Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.60.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.